Advancing human health through rigorous research, ethical trials, and breakthrough therapies. Access real-time updates on our global clinical pipeline.
AZT-909 demonstrated statistically significant improvement in motor function and disease progression markers compared to placebo, marking a pivotal moment in rare disease treatment. Top-line data will be presented at the upcoming International Congress of Gene Therapy.
The designation is based on preliminary clinical evidence showing potential to substantially improve safety or efficacy compared to available interventions.
Comprehensive review of safety and efficacy data across 14 active programs, including positive interim analysis for AZT-774 in metastatic melanoma.
Joint venture will leverage Aevum Zenth's proprietary quantum computing infrastructure to optimize molecular modeling and reduce lead optimization timelines by 40%.
Phase 2b trial for cardiometabolic syndrome now enrolling across 28 countries, aiming to diversify genetic representation in clinical data sets.
Committee for Medicinal Products for Human Use recommends approval, paving the way for broader access to pediatric treatment options across the EU.
Five-year post-marketing surveillance data demonstrates sustained glycemic control and favorable cardiovascular risk profile across 12,000 patients.
High-priority programs advancing through development phases.